Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 2 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 2 of 10.)

DateHeadlineEventSource5-minTo close
Products That Count Announces Winners of the 2026 Q2 Product Awards in Fintech, Cybersecurity, and HealthcarePress releasePR Web+0.10%+0.18%
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF PlatformPress releaseBusiness Wire-0.34%-1.72%
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravisPress releasePR Newswire+0.15%+0.67%
Form 11-K JOHNSON & JOHNSON For: Dec 31SEC filing · Form 11-KSEC EDGAR+0.68%+2.62%
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, FloridaPress releaseBusiness Wire-2.04%-1.40%
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myelomaPress releasePR Newswire-2.04%-1.40%
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapiesPress releasePR Newswire+0.18%-0.70%
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and PatientsPress releaseBusiness Wire+0.18%-0.70%
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos TrialPress releaseBusiness Wire-0.04%-0.47%
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate PlatformPress releaseBusiness Wire+0.65%-0.26%
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 studyPress releasePR Newswire+0.59%+0.35%
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's diseasePress releasePR Newswire+0.59%+0.35%
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigmPress releasePR Newswire-0.50%+0.14%
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limitedPress releasePR Newswire-0.50%+0.14%
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myelomaPress releasePR Newswire-0.30%-2.55%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancerPress releasePR Newswire+0.23%-0.04%
FDA approves label expansion, cementing TREMFYA® as the only IL-23 inhibitor proven to help stop further joint damagePress releasePR Newswire-0.30%-2.55%
Form SD JOHNSON & JOHNSONSEC filing · Form SDSEC EDGAR-0.02%-0.09%
Johnson & Johnson to Host Investor Conference Call on Second-Quarter ResultsPress releaseBusiness Wire-0.02%-0.09%
DePuy Synthes Announces Agreement to Acquire Miniature Radiofrequency Tracking Technology Across its Joint Reconstruction PortfolioPress releaseBusiness Wire-0.49%-1.21%
DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSISPress releaseBusiness Wire-0.49%-1.21%
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovationPress releasePR Newswire+0.38%-1.76%
Form 13F-HR JOHNSON & JOHNSON For: Mar 31SEC filing · Form 13F-HRSEC EDGAR-0.65%-0.09%
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL CatheterPress releaseBusiness Wire-0.04%+0.54%
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCPPress releasePR Newswire+0.10%+0.05%
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferencePress releaseBusiness Wire-0.04%+0.54%
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for RemissionPress releasePR Newswire-0.70%-1.01%
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic SystemPress releaseBusiness Wire-0.01%+0.07%
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel diseasePress releasePR Newswire-0.01%+0.07%
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's diseasePress releasePR Newswire-0.01%+0.07%
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysisPress releasePR Newswire-0.11%-0.58%
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor RelationsPress releaseBusiness Wire+0.21%+0.83%
Form 8-K JOHNSON & JOHNSON For: Apr 23SEC filing · Form 8-KSEC EDGAR+0.02%+0.03%
FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)Press releasePR Newswire+0.58%-0.19%
Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions ConferencePress releaseBusiness Wire+0.02%+0.03%
Form 10-Q JOHNSON & JOHNSON For: Mar 29SEC filing · Form 10-QSEC EDGAR-0.13%+1.17%
IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)Press releasePR Newswire+0.47%-0.04%
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026Press releaseBusiness Wire-1.02%-1.39%
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare ConferencePress releaseBusiness Wire+0.47%-0.04%
Imaging science research gives new clarity on what color helps eyes focus bestPress releasePR Web-0.31%-0.54%
Johnson & Johnson to Participate in the Bank of America 2026 Healthcare ConferencePress releaseBusiness Wire-0.30%-1.21%
Form 8-K JOHNSON & JOHNSON For: Apr 14SEC filing · Form 8-KSEC EDGAR+1.62%+2.61%
Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%Press releaseBusiness Wire+1.62%+2.61%
Johnson & Johnson reports Q1 2026 results, raises 2026 outlookPress releaseBusiness Wire+1.62%+2.61%
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of VisionPress releaseBusiness Wire-1.25%-1.46%
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in EuropePress releaseBusiness Wire-1.35%-0.98%
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once-daily pill for plaque psoriasisPress releasePR Newswire-1.07%-0.43%
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptidePress releasePR Newswire+0.27%-0.25%
Form 13F-HR/A JOHNSON & JOHNSON For: Dec 31SEC filing · Form 13F-HRSEC EDGAR+0.00%+0.08%
Form 13F-HR/A JOHNSON & JOHNSON For: Sep 30SEC filing · Form 13F-HRSEC EDGAR-0.20%-0.08%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground